Skip to content
10-Q

Quarterly Report

INHIBRX BIOSCIENCES, INC. INBX

0002007919-25-000056

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 14.48M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $98.65M
Long Term Debt Q1 2025 · Dec 31, 2024 $0
Cash And Equivalents Q1 2025 · Mar 31, 2025 $216.52M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $152.6M
Current Liabilities Q1 2025 · Mar 31, 2025 $43.64M
Current Liabilities Q1 2025 · Dec 31, 2024 $40.73M
Total Liabilities Q1 2025 · Mar 31, 2025 $148.2M
Total Liabilities Q1 2025 · Dec 31, 2024 $47.18M
Current Assets Q1 2025 · Mar 31, 2025 $223.39M
Current Assets Q1 2025 · Dec 31, 2024 $160.4M
Total Assets Q1 2025 · Mar 31, 2025 $242.64M
Total Assets Q1 2025 · Dec 31, 2024 $180.77M
Revenue Q1 2025 · Mar 31, 2025 $0
Revenue Q1 2025 · Mar 31, 2024 $0
Shares Diluted Q1 2025 · Mar 31, 2024 13.64M sh
Capex Q1 2025 · Mar 31, 2024 $1.12M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$63.05M
Stockholders Equity Q1 2025 · Mar 31, 2024 $11.57M
Stockholders Equity Q1 2025 · Dec 31, 2023 $43.5M
Eps Diluted Q1 2025 · Mar 31, 2024 −$5.77
Eps Basic Q1 2025 · Mar 31, 2024 −$5.77
Sga Expense Q1 2025 · Mar 31, 2024 $9.97M
Rd Expense Q1 2025 · Mar 31, 2024 $63.85M
Net Income Q1 2025 · Mar 31, 2024 −$78.71M
Operating Income Q1 2025 · Mar 31, 2024 −$73.83M